I got my start in biochemistry because of the Vietnam War. As I was finishing my medical residency at Massachusetts General Hospital in 1963, I had two choices going forward: either I could go to Vietnam as a physician, or I could become a research associate in the United States Public Health Service at the National Institutes of Health (NIH). The choice was easy. I considered several laboratories at NIH. I could choose freely because research associates came with their own salaries, so they had no effect on the budget of the laboratory in which they worked. I decided to work in the laboratory of biochemistry at the then-National Heart Institute headed by Earl Stadtman. The laboratory was composed of several sections, each headed by an independent investigator. One was headed by Dr. P. Roy Vagelos. I was drawn to Vagelos' laboratory, as he was very personable, had a background as an M.D., and had children the same ages as mine. The subject of the research did not matter much to me, as I had essentially no previous laboratory experience. At the time, Vagelos was trying to work out the pathway for fatty acid biosynthesis in Escherichia coli. The topic was controversial in that Frédéric Lynen had proposed that fatty acid synthesis was merely a reversal of the steps in fatty acid ␤-oxidation. Vagelos thought this was unlikely and posited a unique pathway for fatty acid synthesis (1) . The first clue that fatty acid synthesis was different was the discovery that bicarbonate was required for synthesis of malonylCoA, which provided the two carbon units for long-chain fatty acids, rather than acetyl-CoA, as in ␤-oxidation (1). In E. coli, Roy had shown that the intermediates in fatty acid synthesis were all covalently bound to a heat-stable protein called enzyme II. My project in the laboratory was to isolate and characterize this factor. The purification proved easy because its stability in both heat and acid made for great early steps. Less than one year after coming to the laboratory, I had my first paper (2) . Over the next two years, Roy, Al Alberts, and I worked out all the reactions of fatty acid synthesis, in which all of the steps used substrates bound to acyl carrier protein (3) (4) (5) (6) (7) .
An aside about Al Alberts: he was a technician on paper but had the greenest thumb I have ever seen for laboratory work. I teased that, if you locked Al in a laboratory with only the reagents and chemicals contained there and returned three weeks later, Al would have a new project up and running. In the future, he would become a full professor of biochemistry at Washington University in St. Louis. After leaving academia to join Vagelos at Merck, Al discovered the statin that became a billion dollar drug for Merck.
The time at NIH was very exciting and rewarding. The Vagelos and Majerus families became very close, sharing ski vacations and Christmas Eves together. Although Roy was only seven years older that I, he was a mentor, both scientifically and in my personal and professional decisions. He always seemed to have time for me. At one point in my career, I was offered a job as head of research and development at a biotech company. At the time, Roy was chief executive officer at Merck. I called Roy for advice, and he said I should fly to Newark, New Jersey, and he would pick me up there and then take me home for discussions. Roy pointed out that such a position would require many aspects that would remove me from day-to-day management of my laboratory. The money meant little to me, and I did not want to give up laboratory work, so I decided that I did not want the job.
When the time came to find a job, I had several offers from basic science departments but only one from a clinical department. This offer was to join the hematology division at Washington University in St. Louis. Even though I had no training in hematology, the chairman, Dr. Carl Moore, said that I could learn on the job. At the same time, he made a similar offer to my colleague Stuart Kornfeld. We learned hematology together and have remained lifelong friends since joining the faculty in 1966. Ironically, after I accepted the job at Washington University, Roy Vagelos was named chairman of the biochemistry department, following Nobel Laureate Carl Cori in that position. Thus, the Vagelos and Majerus families moved to St. Louis at the same time, and our Christmas Eves and ski trips continued. In 1972, Roy was elected to the National Academy of Sciences. Our photograph from the celebration is shown in Fig. 1 .
When I got to St. Louis, I continued my studies of the structure and function of acyl carrier protein (8, 9) . It soon became clear, however, that working on fatty acid synthesis in E. coli was not going to cut it in a hematology division, so Kornfeld and I made a conscious effort to switch to research in hematology. My first efforts included publications on a variety of hematological topics over the next five years. During that period, I isolated the enzymes for glutathione synthesis from human erythrocytes and described a family with hereditary hemolytic anemia caused by glutathione synthetase deficiency (10 -12) . With a postdoctoral fellow, Bob Allen, we developed a method for isolating B 12 -binding proteins by attaching the vitamin to Sepharose for affinity chromatography. We isolated and characterized the intrinsic factor transcobalamin II as well as the other blood B 12 -binding proteins (13) (14) (15) . Bob used these proteins in his later work to devise new and vastly improved methods for measuring B 12 in blood.
My big break came from studies of aspirin. I knew from my work with acyl carrier protein that acetic anhydride could be used to modify lysine residues covalently. Examining the structure of aspirin, I realized that it was a mixed anhydride of acetic and salicylic acids. Therefore, I concluded that aspirin was a reactive compound that could modify proteins. At the time, it was known that many patients who took aspirin suffered from easy bruising, suggesting some effect on the coagulation system. With Jerry Roth, a postdoctoral fellow, we devised a method to tritiate aspirin on a very small scale, on either the ring or the acetyl group. Our first experiments were to add aspirin to various coagulation factors, but to no avail. Finally, in desperation, Jerry added the labeled aspirin to platelets. Bingo! He found that acetyl-labeled aspirin labeled a single protein in platelet membranes. Ring-labeled aspirin did not label platelets, suggesting that the reaction involved acetylation. The labeling saturated at low concentrations of aspirin, and if platelets came from donors who had ingested aspirin, no labeling was observed. The full ability to label platelets returned only after two weeks after aspirin ingestion by the donor, indicating that acetylation persisted for the life of the platelet. In fact, the dose of aspirin needed to fully label platelets was less than 100 mg, much less than that needed for the analgesic and anti-inflammatory uses of the drug (16 -18) . The protein acetylated was prostaglandin synthetase, which, in platelets, leads to formation of the vasoconstricting and platelet-activating thromboxane. J. B. Smith and A. L. Willis had shown previously that aspirin inhibited platelet prostaglandin synthesis (19) . The properties of this reaction suggested that aspirin might be an effective antithrombotic agent at low doses. We decided to do a clinical trial, which was very easy in the days before institutional review boards. We decided to try aspirin as an agent to prevent shunt thrombosis in patients undergoing hemodialysis. Late one afternoon, I looked in the St. Louis phone directory for aspirin and found a company in town (Rexall) that made aspirin tablets. I called after hours, and a man answered the phone. I explained what I wanted: 100 bottles of 160-mg aspirin and the same of a matched placebo. The man said he could make them without any problem and would deliver them to my laboratory the next morning at no charge. Thus, we did the first randomized, controlled trial of aspirin for prevention of thrombosis, and it worked (20) . Later, aspirin was shown to reduce thrombosis in myocardial infarction, stroke, and several other conditions with increased risk for thrombosis.
During the late 1970s and early 1980s, the laboratory studied many aspects of blood coagulation and its relationship to platelet activation. These studies included the isolation and characterization of human factor V (21) and human factor VII (22) . We also showed that prothrombin activation and thrombin formation occur on the surface of activated platelets and are greatly accelerated at that site (23) . Thrombin formation on the surface of platelets was accelerated 15-fold compared with rates of formation by phospholipids, factor Xa, factor Va, and prothrombin (23) . We also isolated human thrombomodulin, a protein discovered by Charles Esmon, and cloned a cDNA encoding the protein (24, 25) .
Work in the laboratory took a major turn when we began to investigate the source of arachidonic acid used for thromboxane formation. There is no free arachidonic acid in plasma, so the source had to be from a phospholipid. We found that the source was phosphatidylinositol (PI). When platelets are activated by thrombin, the levels of PI fall by 40% within 30 seconds and return to base line by 8 minutes (26) . This finding led to a shift in the laboratory to studies of PI metabolism. We isolated the first phospholipase C enzymes (27) and showed that these enzymes hydrolyzed not only PI but also PI(4)P and PI(4,5)P 2 , thereby explaining the route for formation of inositol 1,4,5-trisphosphate, the calcium-mobilizing second messenger molecule (28) . Full elucidation of the scope of phospholipase C enzymes was accomplished later by the laboratory of Sue Goo Rhee (reviewed in Ref. 29) .
In 1986, I was elected to the National Academy of Sciences, and Roy Vagelos immediately flew to St. Louis to celebrate the occasion (Fig. 2) .
Further studies of PI metabolism resulted in the discovery of phosphatases that hydrolyzed phosphates from the 1-, 3-, 4-, and 5-positions of inositol. In some cases, multiple genes were found to carry out the same reactions. We isolated and characterized 5-phosphatase enzymes that cleave inositol 1,4,5-trisphosphate, inositol 1,3,4,5-tetrakisphosphate, and the phospholipids PI(4,5)P 2 and PI(3,4,5)P 3 (30, 31) . There are ten mammalian and four yeast 5-phosphatase genes. We also discovered, isolated, and cloned two genes encoding 4-phosphatases that cleave PI(3,4)P 2 , inositol 1,3,4-trisphosphate, and inositol 3,4-bisphosphate (32, 33) . John York, a graduate student in the laboratory, and I also identified a 1-phosphatase that cleaves inositol 1,4-bisphosphate and inositol 1,3,4-trisphosphate (34) . A cDNA encoding the enzyme was cloned, and the crystal structure was solved (35, 36) . John York and his wife, Sally York, M.D./Ph.D., have become our closest friends over the ensuing years, and we spend most of our vacations with them.
We purified and characterized a 3-phosphatase that cleaves PI(3)P and PI(3,5)P 2 (37) . This phosphatase was the first member of a large family of such 3-phosphatases that is made up of sixteen members designated as myotubularin and myotubularin-related proteins (MTMR1-MTMR15). Nine members of the family contain the catalytic motif CX 5 RT, whereas the other six members lack a catalytic site. In general, the active partners form heterodimers with inactive subunits. Dimer formation is important for function-increasing activity, altering subcellular location, and changing other catalytic properties. Despite the fact that all catalyze the same reactions, they are not redundant in function (29) .
We also isolated and cloned a cDNA encoding inositolpolyphosphate 5/6-kinase (ITPK1) (38) . This enzyme catalyzes the phosphorylation of inositol 1,3,4-trisphosphate to a mixture of inositol 1,3,4,6-tetrakisphosphate and inositol 1,3,4,5-tetrakisphosphate. Inositol 1,3,4,6-tetrakisphosphate is the first product on the pathway for the synthesis of inositol hexakisphosphate (IP 6 ) and the pyrophosphates IP 7 and IP 8 . Mouse knock-out of the genes encoding the enzymes that form IP 5 and IP 6 resulted in an embryonic lethal phenotype, indicating that IP 6 is essential for life (39, 40) . We attempted to create a mouse knock-out of ITPK1 using a gene trap construct, but we got a hypomorphic allele with low levels of active enzyme. The mice were born, but some embryos suffered from neural tube defects, both spina bifida and exencephaly (41) . This phenotype closely resembles that of folate-resistant neural tube defects in humans. Most recently, we discovered two genes encoding PI(4,5)P 2 4-phosphatase activity, thereby providing a route for synthesis of PI(5)P, the most recently discovered inositol lipid. This lipid forms complexes with nuclear ING2, which stimulates acetylation of p53 and increases apoptosis (42, 43) .
The identification of all of these enzymes has allowed investigators who positionally clone disease genes to determine that the mutations are in enzymes of inositol metabolism. These include Lowe syndrome, from mutation of an X-linked 5-phosphatase (OCRL); weeble mouse syndrome, from mutation of inositol-polyphosphate 4-phosphatase type I; myotubular myopathy, from mutation of myotubularin; Charcot-Marie-Tooth disease type 2b, from mutation of MTMR2 or its inactive partner MTMR13; and pale tremor mouse neurodegeneration, from mutation of a 5-phosphatase that cleaves PI(3,5)P 2 . In humans, mutations of this enzyme cause Charcot-Marie-Tooth disease type 4j. MORM (mental retardation, truncal obesity, retinal dystrophy, micropenis) syndrome results from a mutation that deletes the CAAX box in inositol-polyphosphate 5-phosphatase type IV, and Joubert syndrome results from mutations in the catalytic domain in this same enzyme (reviewed in Ref. 29) . In most of these cases, it is not at all clear how mutation of the particular enzyme leads to disease. Inositol phosphates and lipids are involved in myriad signaling reactions and function in cell proliferation, vesicle trafficking, mRNA export from the nucleus, calcium mobilization, and many other processes. The scope of inositol signaling reactions is shown in Fig. 3 .
Undoubtedly, many more mutations in genes of PI metabolism will be found to cause diseases in the future. It is striking that, to date, all mutations cause diseases of the nervous system, perhaps resulting from the fact that signaling reactions are central to brain and nerve function. The laboratory continues to explore other aspects of inositol metabolism. In particular, we are studying the homologous family of MRMR6, MRMR7, and MRMR8, all of which partner with inactive MTMR9. We have recently made a mouse knock-out of MTMR9, which should abrogate the function of all three active members of the family, thereby revealing their function. Thus, I am optimistic that the future portends many interesting findings.
